Medicine and Dentistry
Cohort Analysis
100%
Diffuse Large B-Cell Lymphoma
96%
Non-Hodgkin Lymphoma
56%
Overall Survival
55%
Malignant Neoplasm
50%
Hazard Ratio
43%
COVID-19
43%
Diseases
41%
Acute Myeloid Leukemia
37%
Population
30%
Lifespan
30%
Follicular Lymphoma
29%
Severe Acute Respiratory Syndrome Coronavirus 2
29%
Oncology
27%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
26%
Hodgkin's Lymphoma
26%
Burkitt's Lymphoma
24%
Infection
24%
Second Cancer
24%
Retrospective Cohort Study
24%
High Dose Chemotherapy
24%
Neonates
24%
Phototherapy
24%
Bilirubin
24%
Clinical Trial
22%
Mortality
21%
Event Free Survival
21%
Drug Megadose
20%
International Prognostic Index
19%
Psychoactive Drug
18%
Myelodysplastic Syndrome
18%
Symptom
17%
Diagnosis
16%
Personalized Medicine
16%
Progression Free Survival
15%
Cardiovascular Disease
15%
Patient with Non-Hodgkins Lymphoma
15%
Stem Cell Transplant
14%
Assisted Reproductive Technology
13%
Aggressive Lymphoma
13%
Mental Health
13%
Childbirth
13%
Health Care
12%
Multiple Myeloma
12%
B-Cell Lymphoma
12%
Large-Cell Lymphoma
12%
Alzheimer's Disease
12%
Sex Difference
12%
Work Disability
12%
Post Treatment Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
89%
Diffuse Large B Cell Lymphoma
67%
Acute Myeloid Leukemia
61%
Malignant Neoplasm
56%
Overall Survival
55%
Remission
37%
Nonhodgkin Lymphoma
36%
Psychotropic Agent
30%
Chemotherapy
30%
Follicular Lymphoma
29%
Myelodysplastic Syndrome
26%
Progression Free Survival
24%
Second Cancer
24%
Infection
24%
High Dose Chemotherapy
24%
Clinical Trial
22%
Disease
19%
Large Cell Lymphoma
18%
Methotrexate
16%
Event Free Survival
15%
SARS Coronavirus
14%
Comorbidity
13%
Chimeric Antigen Receptor
13%
Burkitt's Lymphoma
13%
Patient Registry
12%
Life Expectancy
12%
Alzheimer's Disease
12%
Hodgkin Disease
12%
Bendamustine
12%
Alendronic Acid
12%
Primary Central Nervous System Lymphoma
12%
Bilirubin
12%
Obesity
12%
Survival Prediction
12%
Peripheral T Cell Lymphoma
12%
Chemokine Receptor CXCR4 Antagonist
12%
Prednisolone
12%
Case-Control Study
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
12%
B Cell Lymphoma
12%
Myeloproliferative Neoplasm
12%
Hemodialysis
12%
Cardiovascular Disease
12%
Solid Malignant Neoplasm
11%
Multiple Myeloma
10%
Rituximab
10%
Glucocorticoid
8%
Symptom
7%
Statin (Protein)
7%
Congestive Heart Failure
6%
Keyphrases
Lymphoma
39%
National Cohort Study
36%
Lymphoma Patients
35%
High Risk
24%
Reproduction Pattern
24%
Denmark
24%
Second Primary Malignancy
24%
Cure Model
24%
Indolent Lymphoma
18%
Hodgkin Lymphoma
13%
Acute Myeloid Leukemia
13%
Statistical Cure
13%
Plerixafor
12%
Sweden
12%
CXCR4 Antagonist
12%
High-dose Methotrexate (HD-MTX)
12%
Overall Survival
12%
Aggressive B-cell Lymphoma
12%
Danish Population
12%
Matched Cohort Study
12%
Population-based Retrospective Cohort Study
12%
Multiplexed Proteomics
12%
Predictors of Infection
12%
Survival Prediction Model
12%
Work Disability
12%
Turquoise
12%
Light-emitting Diode (LED) Lamps
12%
Blue Light-emitting Diodes
12%
Molecular Classification
12%
Return to Work
12%
Pandemic Waves
12%
Autologous Hematopoietic Stem Cell Transplantation
12%
Bone Mineral Density
12%
Loss of Life Expectancy
12%
CNS Prophylaxis
12%
High-dose Chemotherapy
12%
Background Population
12%
Childbirth
12%
Temporal Change
12%
Swedish Population
12%
Flexible Parametric Model
12%
Lifetime Function
12%
Osteoporosis
12%
Population-based Study
12%
Vertebral Bone Quality
12%
Adult Patients
12%
Population-based
12%
Norway
12%
Bendamustine
12%
Microarray Classification
12%